中华肝胆外科杂志
中華肝膽外科雜誌
중화간담외과잡지
CHINESE JOURNAL OF HEPATOBILIARY SURGERY
2012年
5期
381-385
,共5页
肝癌%凋亡%凋亡抑制蛋白,XIAP%凋亡诱导配体,TRAIL%siRNA%Embelin
肝癌%凋亡%凋亡抑製蛋白,XIAP%凋亡誘導配體,TRAIL%siRNA%Embelin
간암%조망%조망억제단백,XIAP%조망유도배체,TRAIL%siRNA%Embelin
Carcinoma,hepatocellular%Apoptosis%XIAP%TRAIL%siRNA%Embelin
目的 研究X-连锁凋亡抑制蛋白(X-linked inhibitor of apoptosis,XIAP) siRNA或XIAP拮抗剂Embelin对肿瘤坏死因子相关凋亡诱导配体(tumor necrosis factor-related apoptosis-inducing ligand,TRAIL)所致肝癌细胞HepG2生长抑制和细胞凋亡的影响.方法 HepG2细胞转染XIAP siRNA或者阴性对照,然后给予TRAIL处理.此外,HepG2细胞给予TRAIL、Embelin或者联合处理.XIAP表达水平变化、生长抑制、caspase-3活性分别用Western blot、MTT测定、caspase-3荧光法检测.切割PARP的表达水平用Western blot测定.结果 XIAP蛋白表达水平在转染XIAP siRNA后显著下调.与阴性对照相比,XIAP siRNA显著增强TRAIL在100 ng/ml(6.8％±1.2％比11.8％±4.0％,P＜0.05)和1000 ng/ml(18.9％±2.0％比26.6％±1.5％,P＜0.01)的生长抑制作用.在转染XIAP siRNA后,TRAIL诱导caspase-3的活性和PARP的切割显著增强.此外,Embelin显著增强TRAIL对HepG2细胞的生长抑制(P＜0.01)、caspase-3活化(P＜0.01)和PAPR切割.结论 XIAP siRNA或Embelin在肝细胞癌的临床治疗方面具有潜在应用前景.
目的 研究X-連鎖凋亡抑製蛋白(X-linked inhibitor of apoptosis,XIAP) siRNA或XIAP拮抗劑Embelin對腫瘤壞死因子相關凋亡誘導配體(tumor necrosis factor-related apoptosis-inducing ligand,TRAIL)所緻肝癌細胞HepG2生長抑製和細胞凋亡的影響.方法 HepG2細胞轉染XIAP siRNA或者陰性對照,然後給予TRAIL處理.此外,HepG2細胞給予TRAIL、Embelin或者聯閤處理.XIAP錶達水平變化、生長抑製、caspase-3活性分彆用Western blot、MTT測定、caspase-3熒光法檢測.切割PARP的錶達水平用Western blot測定.結果 XIAP蛋白錶達水平在轉染XIAP siRNA後顯著下調.與陰性對照相比,XIAP siRNA顯著增彊TRAIL在100 ng/ml(6.8％±1.2％比11.8％±4.0％,P＜0.05)和1000 ng/ml(18.9％±2.0％比26.6％±1.5％,P＜0.01)的生長抑製作用.在轉染XIAP siRNA後,TRAIL誘導caspase-3的活性和PARP的切割顯著增彊.此外,Embelin顯著增彊TRAIL對HepG2細胞的生長抑製(P＜0.01)、caspase-3活化(P＜0.01)和PAPR切割.結論 XIAP siRNA或Embelin在肝細胞癌的臨床治療方麵具有潛在應用前景.
목적 연구X-련쇄조망억제단백(X-linked inhibitor of apoptosis,XIAP) siRNA혹XIAP길항제Embelin대종류배사인자상관조망유도배체(tumor necrosis factor-related apoptosis-inducing ligand,TRAIL)소치간암세포HepG2생장억제화세포조망적영향.방법 HepG2세포전염XIAP siRNA혹자음성대조,연후급여TRAIL처리.차외,HepG2세포급여TRAIL、Embelin혹자연합처리.XIAP표체수평변화、생장억제、caspase-3활성분별용Western blot、MTT측정、caspase-3형광법검측.절할PARP적표체수평용Western blot측정.결과 XIAP단백표체수평재전염XIAP siRNA후현저하조.여음성대조상비,XIAP siRNA현저증강TRAIL재100 ng/ml(6.8％±1.2％비11.8％±4.0％,P＜0.05)화1000 ng/ml(18.9％±2.0％비26.6％±1.5％,P＜0.01)적생장억제작용.재전염XIAP siRNA후,TRAIL유도caspase-3적활성화PARP적절할현저증강.차외,Embelin현저증강TRAIL대HepG2세포적생장억제(P＜0.01)、caspase-3활화(P＜0.01)화PAPR절할.결론 XIAP siRNA혹Embelin재간세포암적림상치료방면구유잠재응용전경.
Objective To investigate the effects of X-linked inhibitor of apoptosis (XIAP) siRNA or XIAP antagonist Embelin on the growth inhibition and apoptosis of hepatcellular cancer cell line HepG2,which was treated by tumor necrosis factor-related apoptosis (TRAIL). Methods HepG2 cells were tranfected either by XIAP siRNA or a negative control,followed by treatment with TRAIL,Embelin or a combination of the two.XIAP expression,cell growth,and caspase-3 activity were determined by Western blot,MTT assay and fluorescent caspase-3 assay,respectively.Cleaved PARP expression levels of were measured by Western blot.Results The XIAP protein expression was significantly downregulated by transfection with XIAP siRNA.Compared with the negative control,the XIAP siRNA significantly inhibited the growth of HepG2 cells treated by 100ng/ml(6.8％ ±1.2％ vs.11.8％±4.0％,P＜0.05)and 1000 ng/ml (18.9％ ±2.0％ vs.26.6％ ±1.5％,P＜0.01)by TRAIL.TRAIL-induced caspase-3 activation and PARP cleavage were also increased significantly by XIAP siRNA transfection.In addition,Embelin also significantly inhibited cell growth (P＜0.01),activation of caspase-3 (P＜ 0.01) and TRAIL-induced PARP cleavage.Conclusions Both XIAP siRNA and Embelin may potentially contribute to clinical treatment of hepatocellular carcinoma.
